# US 2016/0355582 A1 · Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355582 A1
- Document ID: US20160355582A1
- Status: Published application
- Kind: A1
- Application number: 15/089,285
- Filed: 2016-04-01
- Published: 2016-12-08
- Earliest claimed: 2009-10-22
- Assignees: Universiteit Twente
- Applicants: Universiteit Twente
- Inventors: Hermanus Bernardus Johannes KARPERIEN; Cornelis Theodorus VERRIPS; Mohamed EL KHATTABI; Emilie DOOMS RODRIGUES; Jan DE BOER; Clemens Antoni VAN BLITTERSWIJK; Renee DE BRUIN
- Web page: https://patentgrep.com/patent/US20160355582A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/047: {Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61L 2300/25: Peptides having up to 20 amino acids in a defined sequence
- A61L 2300/432: Inhibitors, antagonists (A61L2300/402 - A61L2300/43 take precedence)
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2319/01: containing a localisation/targetting motif
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.

## Claims

### Claim 1

A single heavy chain variable domain antibody (VHH) which binds to a growth factor or to an antagonist of said growth factor, which VHH is functionalized to bind to an implant.

### Claim 2 (depends on 1)

A VHH according to claim 1, wherein said growth factor comprises a Transforming growth factor beta (TGFbeta), Hedgehog, Wnt, Epidermal growth factor (EGF), a Bone Morphogenic Protein (BMPs), or a Fibroblast growth factor (FGF), or wherein said antagonist comprises a BMP antagonist, a Wnt-antagonist, or wherein said antagonist comprises a dual antagonist of BMP and Wnt.

### Claim 3 (depends on 1)

A VHH according to claim 1, wherein the implant comprises a biomaterial selected from the group consisting of hyaluronic acid, chitosan, dextran, hyaluronic acid, heparin, heparan starch, poly lactic acid (PLA), a polyalkyleneoxide-polyalkyle-terephtalate block copolymer, poly-L-lactic acid (PLLA), polyglycolic lactic acid (PGLA), polyglycolic acid (PGA), poly(amido amine)s, poly(caprolactone), polyethylene, a gel based on alginate, a Poly-N-isopropylacrylamid gel, PEG-PBT, a biocompatible ceramic, hydroxyapatite, calciumphosphate or biocompatible glass, or a biocompatible metal coated with hydroxyapatite or calciumphosphate.

### Claim 4 (depends on 1)

A VHH according to claim 1, wherein said VHH comprises an amino acid sequence selected from the group of amino acid sequences listed in Table 1, Table 2 and Table 3.

### Claim 5 (depends on 1)

A VHH according to claim 1, wherein said VHH comprises a functional group which binds an implant via chemical crosslinking.

### Claim 6 (depends on 5)

A VHH according to claim 5, wherein said functional group is:
a. a glycosyl group attached at one of the VHH's short loops 1, 2, 3, 5 as indicated in FIG. 5, or
b. a peptide bound to said VHH via a cysteine or methionine residue present in the last 10 amino acids of the C terminal end of said VHH, with the exception of the last amino acid.

### Claim 7 (depends on 5)

A VHH according to claim 5, wherein said functional group is an unnatural amino acid that cross links to respective residues in an implant or links to an implant through NHS chemistry.

### Claim 8 (depends on 1)

A VHH according to claim 1, wherein said VHH comprises an amino acid sequence which binds to an implant.

### Claim 9 (depends on 8)

A VHH according to claim 8, wherein the VHH amino acid sequence is selected from the group consisting of the amino acid sequences listed in Table 8.

### Claim 10 (depends on 1)

A fusion protein comprising at least two VHHs of claim 1, wherein at least one VHH binds to a growth factor and/or to an antagonist of said growth factor, and at least one VHH which binds to an implant.

### Claim 11 (depends on 10)

A fusion protein according to claim 10, wherein said growth factor comprises a Transforming growth factor beta (TGFbeta), Hedgehog, Wnt, Epidermal growth factor (EGF), a Bone Morphogenic Protein (BMPs), or a Fibroblast growth factor (FGF), or wherein said antagonist comprises a BMP antagonist, a Wnt-antagonist, or wherein said antagonist comprises a dual antagonist of BMP and Wnt.

### Claim 12 (depends on 10)

A fusion protein according to claim 10, wherein the implant comprises a biomaterial selected from the group consisting of hyaluronic acid, chitosan, dextran, hyaluronic acid, heparin, heparan starch, poly lactic acid (PLA), a polyalkyleneoxide-polyalkyle-terephtalate block copolymer, poly-L-lactic acid (PLLA), polyglycolic lactic acid (PGLA), polyglycolic acid (PGA), poly(amido amine)s, poly(caprolactone), polyethylene, a gel based on alginate, a Poly-N-isopropylacrylamid gel, PEG-PBT, a biocompatible ceramic, hydroxyapatite, calciumphosphate or biocompatible glass, or a biocompatible metal coated with hydroxyapatite or calciumphosphate.

### Claim 13 (depends on 10)

A fusion protein according to claim 10, wherein said fusion protein comprises at least one VHH that binds to a dual antagonist of BMP and Wnt.

### Claim 14 (depends on 10)

A fusion protein according to claim 10, wherein said fusion protein comprises an amino acid sequence selected from the group of amino acid sequences listed in Table 7.

### Claim 15 (depends on 1)

A protein complex comprising a VHH according to claim 1 and a growth factor or antagonist to a growth factor which binds to said VHH.

### Claim 16 (depends on 10)

A protein complex comprising a fusion protein according to claim 10 and a growth factor or antagonist to a growth factor which binds to said fusion protein.
